“…CDK12 has been implicated in cancer pathology, such as cell invasion, suggesting that aberrant CDK12 expression may have oncogenic properties. Thus, this kinase may become a particularly interesting therapeutic target in prostate [ 128 ], esophageal [ 129 ], gastric [ 130 ], breast [ 131 ], endometrial, bladder, uterine, and ovarian [ 132 ], pancreatic [ 133 ], non-small cell lung cancer [ 134 ], lung adenocarcinoma [ 135 ], and follicular lymphoma [ 136 ]. An increasing number of studies point to the role of CDK12, in cell function and cancer, as an effective strategy to inhibit tumor growth, and its potential clinical use as a biomarker.…”